Intuitive Surgical Expects 31% Jump In FY21 Revenues

Intuitive Surgical Inc ISRG posted interim Q4 sales of $1.55 billion, +17% Y/Y, better than the consensus of $1.51 billion.

  • Preliminary 2021 revenue of approximately $5.71 billion increased 31% Y/Y, ahead of analysts' estimate of $5.68 billion.
  • Q4 2021 worldwide da Vinci procedures grew approximately 19% compared with Q4 FY20.
  • Intuitive Surgical shipped 385 da Vinci Surgical Systems in Q4 FY21, +18%. The company shipped 1,347 da Vinci Surgical Systems in 2021, an increase of 44%.
  • Related: Intuitive's Q3 Earnings Slightly Edges Out Expectations.
  • Interim Q4 instruments and accessories revenue increased by 13% to approximately $843 million, primarily driven by da Vinci procedure volume growth.
  • Fourth-quarter 2021 systems revenue increased by 28% to approximately $470 million.
  • In December 2021, the company received FDA clearance for the 8 mm SureForm 30 Curved-Tip Stapler and reloads for use in general, thoracic, gynecologic, urologic, and pediatric surgery. 
  • The company noted that COVID-19 would likely continue to have an adverse impact on its procedure volumes.
  • Price Action: ISRG shares are down 1.38% at $323.63 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!